Related Experiment Video
Updated: Jul 14, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Glycolytic activity following anti-CD19 CAR-T cell infusion in non-Hodgkin lymphoma
Nicolas Vallet1,2, Laurianne Drieu Larochelle1, Maria-Joao Santiago-Ribeiro3
1Hematology and Cell Therapy, University Hospital Tours, Tours, France.
Abstract:
Energy metabolism of chimeric antigen receptor-T cells (CAR-T) activation in humans remains unexplored. As a glycolytic activity surrogate, we investigated the dynamics of peripheral blood (PB) lactate in the first weeks post-CAR-T infusion. In 17 patients treated with CD28 harbording anti-CD19 CAR-T for relapsed/refractory non-Hodgkin lymphomas, PB lactate levels increased following CAR-T infusion. Elevated lactate levels correlated with longer CAR-T persistence and higher CD8+/CD4+ ratio. Peripheral blood lactate kinetics may reflect immune cells activation and be useful for bedside monitoring.
